Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of “Hold” by Analysts

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has received a consensus rating of “Hold” from the twelve research firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $56.8889.

A number of equities analysts recently commented on IMCR shares. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research note on Wednesday. Jefferies Financial Group started coverage on shares of Immunocore in a research note on Monday, August 25th. They issued a “buy” rating and a $48.00 price objective for the company. Zacks Research downgraded shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 4th. Finally, Guggenheim started coverage on shares of Immunocore in a research note on Thursday, September 18th. They issued a “neutral” rating for the company.

Immunocore Stock Performance

Immunocore stock opened at $32.40 on Tuesday. The company has a 50 day moving average price of $33.69 and a 200-day moving average price of $32.43. The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.86 and a current ratio of 5.89. Immunocore has a fifty-two week low of $23.15 and a fifty-two week high of $39.33. The company has a market capitalization of $1.63 billion, a PE ratio of -81.00 and a beta of 0.79.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.01. The firm had revenue of $130.65 million during the quarter, compared to the consensus estimate of $122.96 million. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The company’s revenue was up 30.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. As a group, equities analysts forecast that Immunocore will post -0.94 earnings per share for the current year.

Insider Activity

In other news, insider David M. Berman sold 22,532 shares of the company’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $35.67, for a total transaction of $803,716.44. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Immunocore

A number of large investors have recently made changes to their positions in IMCR. GAMMA Investing LLC increased its position in shares of Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after purchasing an additional 311 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Immunocore by 4,696.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after purchasing an additional 1,268 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new position in shares of Immunocore during the second quarter worth $42,000. Osaic Holdings Inc. increased its position in shares of Immunocore by 117.4% during the second quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after purchasing an additional 1,700 shares in the last quarter. Finally, State of Tennessee Department of Treasury acquired a new position in shares of Immunocore during the second quarter worth $132,000. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.